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Efficacy of Fluor ine-18 -Deoxyglucose Posi tron Emiss ion
Tomography in Detect ing Tumor Recurrence Af ter Local
Ablat i ve Therapy for Liver Metastases : A Prospect i ve Study
By B.S. Langenhoff, W.J.G. Oyen, G.J. Jager, S.P. Strijk, Th. Wobbes, F.H.M. Corstens, and T.J.M. Ruers
Purpose: The aims of this prospective study were to
investigate the potential role of fluorine-18-deoxyglucose
(FDG) positron emission tomography (PET) in determining
the efficacy of the local tumor ablative process and to
determine the added value of FDG-PET in the detection of
tumor recurrence during follow-up.
Patients and Methods: Twenty-three patients with unre-
sectable colorectal liver metastases were followed up after
local ablative therapy consisting of a standard protocol includ-
ing FDG-PET scanning, computed tomography (CT) scanning,
and carcinoembryonic antigen measurements. The mean fol-
low-up period was 16 months (range, 10 to 21 months).
Results: Ninety-six lesions was treated, 56 by local ab-
lative treatment. Within 3 weeks after local ablative treat-
ment, 51 lesions became photopenic on FDG-PET, while five
lesions (in five patients) showed persistent activity on FDG-
PET. In four of five FDG-PET–positive lesions, a local recur-
rence developed during follow-up; one FDG-PET–positive
lesion turned out to be an abscess. None of the FDG-PET–
negative lesions developed a local recurrence during a
mean follow-up period of 16 months. During follow-up, 11
patients showed recurrence in the liver outside of the
treated area. In all cases, previously negative FDG-PET
scans became positive. Extrahepatic recurrence was en-
countered in nine patients during follow-up; FDG-PET
showed all nine cases of tumor recurrence. There was one
false-positive FDG-PET caused by an intra-abdominal ab-
scess. In all patients, the time point of detection of recur-
rence by FDG-PET was considerably earlier than the detec-
tion by CT.
Conclusion: FDG-PET seems to have a significant impact
in measuring treatment efficacy directly after local ablative
therapy. Furthermore, FDG-PET has an added value in pa-
tient follow-up because it reveals recurrences earlier than
conventional diagnostic modalities.
J Clin Oncol 20:4453-4458. © 2002 by American
Society of Clinical Oncology.
SURGICAL RESECTION is the treatment of choice inpatients with colorectal liver metastases. The 5-year sur-
vival rate after resection of colorectal liver metastases ranges
between 25% and 40%, with a median survival time between 28
and 46 months.1-6 Recently, local ablative techniques such as
cryosurgery ablation (CSA) and radiofrequency ablation (RFA)
have received considerable attention for the treatment of colo-
rectal liver metastases.7-11 Until now, these techniques have
mainly been used as adjuncts to hepatic resection in patients in
whom complete tumor clearance of the liver cannot be obtained
by resection alone. CSA and RFA are performed during intra-
operative ultrasound monitoring in order to assure complete
tumor treatment. During CSA, an “ice ball” is formed that leads
to a hypoechogenic area which should include all tumor tissue.
During RFA, air bubbles seen in the treated lesion create a
hyperechogenic area.12,13 Despite improvements, the extensive
use of local ablative techniques is still hampered by limitations
in monitoring of the destruction process at the time of treatment.
The frequency of incomplete treatment and hence local recur-
rence after local ablation is relatively high. After CSA, local
recurrence at the cryosite is observed in 2%14 to 44%15 of
patients. For RFA, these figures (lesion-based analysis) range
between 2% and 55%.16
After local ablative therapy, local recurrence and hence
treatment failures are, unless at a late stage, not easily identified
with anatomic imaging modalities such as computed tomography
(CT) scans and ultrasound. With these techniques, normal
postablative treatment effects can hardly be differentiated from
residual tumor or recurrent disease.12 More accurate imaging
modalities evaluating the treatment efficacy of local tumor
ablation will not only improve the evaluation of these new
ablative techniques in liver surgery but also offer the opportunity
for early reintervention by either surgery or repeated local
ablation in case of an insufficient initial treatment result. Positron
emission tomography (PET) with fluorine-18-deoxyglucose
(FDG) is an imaging modality that allows direct evaluation of
cellular glucose metabolism. Being a functional imaging modal-
ity, FDG-PET may be of added value in differentiating between
residual tumor, recurrent disease, and postoperative treatment
effects. In this study, we investigated (1) the potential role of
FDG-PET in measuring the efficacy of local tumor ablation as
well as (2) the added value of FDG-PET in the detection of
tumor recurrence during follow-up.
PATIENTS AND METHODS
Patient Population
Between April 1998 and July 2000, 23 patients with unresectable
colorectal liver metastases were treated using local tumor ablation by means
of CSA or RFA. Local ablation was considered when patients met the
following criteria: (1) metastases confined to the liver and judged unresect-
able due to technical considerations related to location or extent of the
disease; (2) number of metastatic deposits was 10 or less; and (3) local tumor
ablation alone or in combination with resection allowed complete eradication
of tumor from the liver. In all patients, the preoperative work-up consisted of
a CT scan of the abdomen and chest, a whole-body FDG-PET scan, a barium
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enema of the colon or coloscopy, and serum carcinoembryonic antigen
(CEA) measurements. No postoperative adjuvant chemotherapy was given.
Operative Technique
Surgery was performed through an extended right subcostal incision. The
abdominal cavity was thoroughly explored to exclude extrahepatic disease.
Biopsy specimens and fresh frozen sections were taken in case of suspicious
lymph nodes or peritoneal deposits. The liver was mobilized from its
ligamentous attachments, and the extent of the disease was mapped by
careful palpation and intraoperative ultrasound. The number of lesions and
their relationships to the major biliary and vascular structures were deter-
mined, and final resectability was assessed. Large tumor size and locore-
gional invasion of perihepatic structures such as the diaphragm were not
considered a contraindication to operation as long as resection could clear all
tumor tissue. During all surgical procedures, resection was considered to be
the treatment of choice. When complete resection could not be achieved, the
decision was made either to perform CSA or RFA alone or to combine
resection of the resectable lesions with local ablative therapy of unresectable
deposits.17 In general, CSA was used during the early period of the study,
and RFA was used during the last 10 months of the study when this technique
became available in our clinic.
Technique Hepatic Cryosurgery
After localization of the liver metastases, a cryoprobe (LCS 2000;
Spembly Medical, Hampshire, United Kingdom) was introduced under
ultrasound guidance into the center of the tumor. During introduction, major
vascular and biliary structures were avoided. After accurate positioning of
one or more cryoprobe(s), liquid nitrogen was driven through the probe at
196°C. During the freezing process, continuous ultrasound monitoring of
the lesion was carried out to ensure that the ice ball, visible as a
hypoechogenic area around the tip of the cryoprobe, exceeded the diameter
of the lesion by approximately 1 cm. Two freeze-thaw cycles per lesion were
performed. Inflow occlusion (the Pringle maneuver) was sometimes used to
increase the efficacy of the freezing process. In general, separate lesions were
frozen sequentially rather than simultaneously. After completion of the
freezing procedure, cryoprobes were removed and the probe entry site was
filled with fibrin sealant (Tissucol; Baxter, Utrecht, the Netherlands).
Hepatic Radiofrequency Technique
For RFA, the Cool-tip system (Radionics; Tyco Healthcare Group LP,
Burlington, MA) was used. Under ultrasound guidance, the cooled-tip
electrode was placed in the center of the tumor. For lesions smaller than 3 cm
in diameter, a single cooled-tip electrode was used; for lesions larger than 3
cm, RFA was performed with a cooled-tip cluster electrode. For lesions
larger than 4 cm, tumor ablation was achieved by several probe insertions.
RFA is based on alternating current through the tissue, thereby creating
friction on a molecular level. This results in increased intracellular temper-
ature and localized interstitial heating. During the heating process, air
bubbles arise around the tip of the electrode, which creates a hyperechogenic
area around the probe. In RFA, not only should the tumor be necrotized but
also a 0.5- to 1.0-cm thick rim (ie, a surgical safety margin) of peritumoral
liver tissue should be treated in order to destroy infiltrating tumor and reduce
the risk of recurrence.18
Imaging
FDG-PET scanning. A dedicated, rotating, half-ring FDG-PET scanner
(ECAT-ART; Siemens/CTI, Knoxville, TN) was used for data acquisition.
Before injection of FDG, patients fasted for at least 6 hours. Intake of
sugar-free liquids was permitted. Immediately before the procedure, the
patients were hydrated with 500 mL of water. One hour after intravenous
injection of 200 to 220 MBq of FDG (Mallinckrodt Medical, Petten, the
Netherlands) and 20 mg of furosemide, emission images or emission and
transmission images were acquired of the area between the proximal femora
and the base of the skull (10 minutes per bed position). When only an
emission study was recorded, the images were not corrected for attenuation
and reconstructed using filtered backprojection (Butterworth filter with a
cutoff frequency of 0.4 Nyquist). When emission and transmission studies
were recorded, the images were corrected for attenuation and reconstructed
using the ordered subsets expectation maximization algorithm. Recon-
structed images were displayed in coronal, transverse, and sagittal planes.
FDG-PET scans were evaluated by at least two nuclear physicians.
FDG-PET scans obtained immediately after local tumor ablation were
scored for the presence or absence of residual FDG activity. After successful
CSA or RFA, a photopenic area was seen on FDG-PET scans. Areas of focal
FDG accumulation greater than background activity were interpreted as
being pathologic.
CT scanning. CT examinations of the abdomen and chest were per-
formed with a spiral CT scanner Somatom Volume Zoom; Siemens,
Erlangen, Germany). All patients received diluted ionic oral contrast 1 hour
before the CT examination. The liver was scanned before and after
intravenous contrast injection. By use of an Envision CT injector (Medrad,
Pittsburgh, PA) at a rate of 4 mL/sec, intravenous contrast material was
injected through an 18-gauge catheter placed in an antecubital vein. A total
of 100 mL of iohexol nonionic contrast material (Omnipaque, iodine 350
mg/mL; Nycomed, Princeton, NJ) was injected. The liver was scanned in the
venous phase, 70 seconds after start of the injection. Both unenhanced and
enhanced helical sequences were performed at 120 kV and 15 to 300 mAS.
Contiguous reconstructed sections (pitch 1:1) were obtained with 7-mm
collimination. All examination results were stored on an optical disk for further
review. In addition, hard copies of the scans were obtained for both series.
Each hard copy was analyzed separately by two independent reviewers
(G.J., S.P.S.). Consensus was obtained in all cases. Second scans were read
with knowledge of the first scans (reference scans). A sharply demarcated,
hypoattenuated, nonenhanced area, which decreases in size on follow-up
scans, was interpreted to mean there was no residue. An enhanced hyperemic
rim around the margin of the ablated tissue was considered ablation-induced
hyperemia. A faint, irregular, hypoattenuated area around the margins of the
ablated tumor that increased in size on follow-up scans was interpreted as
residual tumor.
Postablation Analysis and Follow-Up
Within 3 weeks after local ablative treatment, FDG-PET, spiral abdominal
CT, and serum CEA measurements were performed. To determine treatment
efficacy, the postoperative and preoperative measurements were compared.
The results of these immediately postoperative investigations became the
reference for further follow-up investigations. After these initial investiga-
tions, standard follow-up consisted of FDG-PET, spiral abdominal CT, spiral
chest CT, and serum CEA measurements at 6 weeks after treatment and
every 3 months thereafter.
Data Analysis
CT and FDG-PET images were evaluated by an independent investigator
blinded to the results of CEA measurements. For every region, the concor-
dance between CT and FDG-PET findings was verified. In case of a
discordance, the FDG-PET findings were compared with the true lesion status,
obtained by histopathologic confirmation (n  1) and/or clinical follow-up by
repeated imaging at least 9 months after the discordant observation.
All recurrences showed a clear tendency to be enhanced on CT and FDG-PET
scans. Discordant findings were subsequently classified as a true-positive,
false-positive, true-negative, or false-negative. The mean follow-up period in this
prospective study was 16 months (range, 10 to 21 months).
RESULTS
Patients and Treatment Characteristics
Seventeen patients were treated by CSA and six patients by
RFA (Table 1). Sixteen of the 23 patients had synchronous
metastases, and seven showed metachronous metastases. The
number of liver lesions per patient varied from one to 10. In all
patients treated by CSA,17 local tumor ablation of unresectable
lesions was performed in combination with hepatic resection of
resectable tumor deposits. Of the six patients who underwent
RFA, two patients were treated with both RFA and hepatic
resection; the other four patients were treated by RFA alone.
The number of nodules treated by CSA and RFA ranged from
one to seven, with a median number of 2.1 lesions for CSA and
3.5 lesions for RFA. The size of the metastases treated by CSA
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varied from 1 cm to 8 cm, and for RFA, from 1 cm to 6 cm. All
patients completed follow-up according to the protocol; there
was no postoperative mortality. However, in one patient, the first
postoperative FDG-PET scan was canceled due to clear abscess
formation in the liver area. The mean follow-up period for
patients was 16 months (range, 10 to 21 months).
Immediately Postoperative Imaging
Patient-based posttreatment analysis. In all 23 patients, CT
scans taken within 3 weeks after local ablative therapy showed
hypodense treatment areas without any evidence of tumor
remnants. Air in the ablated lesions was seen on the initial CT
scan in most cases. An abscess was found in one patient treated
with CSA. In a second patient treated with RFA, initial CT
findings were not specific (enhanced rim and presence of air)
while an abscess developed several weeks after treatment.
Directly after local ablative therapy ( 3 weeks), FDG-PET
was performed for 22 patients. In the patient with an abscess
diagnosed shortly after CSA, FDG-PET scanning was not
performed. In 17 of these 22 patients, the FDG-PET results
became negative after treatment (Table 2). In five patients,
FDG-PET scans remained positive (Fig 1). Three of these five
patients had been treated with CSA and two with RFA. In these
patients, FDG-PET scans showed focally increased activity at
the edge of the treated lesions. Four of these five patients
developed a local recurrence at the ablated site during follow-up.
In two patients with local recurrence at the ablated site, the
tumors were in the proximity of major intrahepatic blood vessels.
One patient treated with RFA seemed to develop an abscess in
the treated area, which led to a false-positive FDG-PET scan. In
patients who also underwent resection, the operation did not
significantly affect FDG-PET scanning because the area of
resection did not provide artifacts on FDG-PET.
Lesion-based posttreatment analysis. In the group of 23
patients, a total of 96 lesions were treated, 56 of them by local
ablative therapy. After treatment, 51 lesions became negative on
FDG-PET scans, while five lesions still showed activity on
FDG-PET scans. In four of five FDG-PET–positive lesions, a
local recurrence was detected within 6 months after treatment;
one FDG-PET–positive lesion turned out to be an abscess (Table
3). Conversely, none of the FDG-PET–negative lesions devel-
oped into a local recurrence during a mean follow-up period of
Table 1. Treatment Characteristics
CSA RFA
No. of patients 17 6
Male/female 11/6 4/2
Age, years
Mean 63.7 62
Range 51-78 53-72
Total no. of treated lesions
Mean 4.1 4.3
Range 1-10 1-10
No. of lesions treated with local ablative therapy
Mean 2.1 3.5
Range 1-7 1-7
Diameter of lesions treated with local ablative therapy, cm
Mean 2.6 2.4
Range 1-8 1-6
With/without additional resection 17/0 2/4
Table 2. Patient-Based Analysis of FDG-PET Immediately After Local Tumor
Ablation
CSA* RFA
No. of patients with positive FDG-PET before treatment 17 6
No. of patients with negative FDG-PET after treatment 13 4
No. of patients with positive FDG-PET after treatment 3 2†
No. of patients who developed local recurrence at
ablated site during follow-up
3 1
*One patient did not have the early postoperative FDG-PET due to an abscess.
†One patient had an abscess.
Fig 1. FDG-PET and CT after treat-
ment: (A) after 3 months, (B) 6 months,
and (C) 9 months. After 3 months, FDG-
PET showed clear FDG accumulation,
revealing residual disease. Abnormali-
ties on CT after 3 and 6 months were
interpreted as posttreatment effects;
while tumor recurrence was diagnosed
on CT after 9 months.
4455EFFICACY OF FDG-PET IN DETECTING LIVER METASTASES
Downloaded from ascopubs.org by Radboud University Nijmegen on December 12, 2019 from 131.174.248.154
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
16 months (range, 10 to 21 months). The positive predictive
value for the detection of local recurrence in lesions with a
positive FDG-PET scan after treatment was 80%; the negative
predictive value was 100%.
Imaging During Follow-Up
Liver. Four patients developed local recurrence at the treated
site. As mentioned earlier, in all of these cases initial FDG-PET
scans (within 3 weeks after local tumor ablation) showed focal
and slightly irregular uptake in the rim of the treated lesion.
Unequivocal diagnosis of local recurrence, however, was made
when abnormal FDG accumulation typically progressed during
follow-up. Therefore, definite diagnosis of local recurrence by
FDG-PET was scored after 0.5, 3, 6, and 6 months. On CT scans,
these recurrences became apparent several months later, at 4, 9,
9, and 12 months, respectively. The mean time point of definite
detection by FDG-PET was 3.8 months, compared with 8.5
months for CT. One patient proved to have an abscess, which led
to a false-positive FDG-PET scan.
Eleven patients developed recurrent disease in the liver
outside the treated area during follow-up. All recurrences were
detected by FDG-PET as well as by CT. The time of detection,
however, varied between FDG-PET and CT. These recurrences
were definitely determined by FDG-PET at 3 months (n  3), 6
months (n  2), 9 months (n  2), 12 months (n  3), and 14
months (n  1) after treatment. On CT scans, these recurrences
became apparent several months later, at 6 months (n  3), 9
months (n  2), 12 months (n  3), 18 months (n  2), and 21
months (n  1). The mean time point of detection by FDG-PET
was 8.1 months, compared with 11.7 months for CT (Table 4).
Extrahepatic. Nine patients developed extrahepatic recur-
rences during follow-up. Two patients had extrahepatic recur-
rences at multiple sites. In six patients, extrahepatic recurrences
were located in the lungs; in one patient, recurrence was located
in the abdominal wall; in three patients, extrahepatic metastases
were intra-abdominal; and one patient had cerebral metastases
(this patient died 10 months after local ablative treatment).
Extrahepatic recurrences were definitely determined by FDG-
PET at 0.5 months (n  1), 6 months (n  3), 9 months (n  2),
12 months (n  2), and 15 months (n  1). In the first patient,
the preoperative FDG-PET scan was suspicious but was judged
not convincing until progression of the lesion on FDG-PET at 2
weeks after surgery. In one patient, a false-positive outcome was
observed because of an extrahepatic abscess. On CT scans,
extrahepatic tumor lesions became apparent several months later,
at 3 months (n  1), 6 months (n  1), 9 months (n  3), 12
months (n  2), and 18 months (n  1). Furthermore, in one
patient pulmonary metastases were initially missed on the CT
scan, while the FDG-PET scan showed obvious multiple pulmo-
nary metastases; however, these metastases could be seen on the
CT scan in retrospect. The mean time point of detection of
extrahepatic recurrence by FDG-PET was 8.4 months, compared
with 9.8 months for CT.
CEA Measurements
CEA seemed not to be a very sensitive indicator for tumor
recurrence. Ten patients did not show an elevated CEA level
before operation (non-CEA secretors). Only 10 (59%) of 17
patients who had a recurrence of disease during follow-up
showed elevated CEA levels ( 5 ng/mL). Of the seven patients
with recurrence and no elevated CEA levels during follow-up,
two patients were non-CEA secretors at the time of the opera-
tion. The other five patients showed normalized CEA levels after
local tumor ablation and did not show any increase of CEA at the
time of recurrence (Table 4).
DISCUSSION
This study shows the potential role of FDG-PET in measuring
the efficacy of local tumor ablation as well as the added value of
FDG-PET in the detection of tumor recurrence during follow-up.
The efficacy of local tumor ablation is an important prognostic
factor for patients undergoing these procedures. During the
process of local ablation, the destruction process cannot easily be
ascertained. Ultrasound monitoring is generally used for initial
positioning of the RFA or cryoprobe and to ascertain whether the
cryolesion seen as a hypoechoic area or the radiofrequency-
treated area seen as a hyperechoic area completely engulfs the
tumor. Whether indeed tumor-cell kill occurs within these areas
is, however, difficult to confirm. Temperatures reached at the
edge of (large) lesions may be inadequate. Furthermore, major
blood vessels may serve as “heat sinks” and prevent adequate
ablation of immediately adjacent tumor. In large lesions, in
which multiple probe insertions are necessary, additional repo-
sitioning of the electrode may become obscured because of the
hypoechoic/hyperechoic focus appearing around the distal probe
Table 3. Lesion-Based Analysis of FDG-PET and Local Recurrence After Local
Tumor Ablation
Recurrence No Recurrence
FDG-PET positive 4 1
FDG-PET negative 0 51
Table 4. Tumor Recurrence During Follow-Up
Total No. of
Patients With
Recurrence
Elevated
CEA*
Mean Time of
Detection of
Recurrence by CEA
(months)
FDG-PET
Positive
Mean Time of
Detection of
Recurrence by PET
(months)
CT
Positive
Mean Time of
Detection of
Recurrence by CT
(months)
Time
Difference in
FDG-PET and
CT Detection
(months)
Local recurrence 4 2 11 5† 3.8 4 8.5 4.7
Liver recurrence outside
treated area
11 7 12.3 11 8.1 11 11.7 3.6
Extrahepatic recurrence 9 5 12.6 10‡ 8.4 8§ 9.8 1.4
*Normal CEA 5 ng/mL.
†One patient had an abscess at the ablated area in the liver.
‡One patient had an extrahepatic abscess.
§In one patient only (in retrospect), pulmonary metastases were visable on spiral chest CT scan.
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during the application of thermal energy. Monitoring of treat-
ment efficacy in these situations again is difficult.
PET using FDG has emerged as a promising diagnostic modality
in patients with colorectal liver metastases. Unlike conventional
diagnostic modalities, such as CT scans and ultrasound, which
require anatomic alterations for detection of malignancy, FDG-PET
provides information on tumor growth based on increased glucose
uptake and metabolism of malignant cells.
In this study, 51 lesions became FDG-PET negative directly
after local ablative therapy, meaning that FDG-accumulating
liver metastases became photopenic. Five lesions remained
FDG-PET positive. In four of five FDG-PET–positive lesions, a
local recurrence was detected within a mean follow-up period of
16 months; one FDG-PET–positive lesion was an abscess.
Conversely, none of the FDG-PET–negative lesions developed a
local recurrence in the liver during follow-up. The positive
predictive value for the detection of local recurrence in lesions
with a positive FDG-PET scan after treatment was 80%; the
negative predictive value was 100%. FDG-PET was able to give
accurate information about eventual local recurrences at a
significantly earlier stage than CT. In the future, this information
initially given by FDG-PET should lead to further investigations
to collect more precise anatomic information, by CT for exam-
ple. In this way, FDG-PET determines the need for further
investigations and guides the reading of the CT scan, which on
its own is difficult to interpret in the early period after local
ablative therapy. This combined information (FDG-PET and CT
scans) offers the opportunity to re-treat tumors at an early stage.
Although the aims of our study were to investigate the potential
role of FDG-PET in determining the efficacy of the local tumor
ablative process and to determine the added value of FDG-PET
in the detection of tumor recurrence during follow-up, we have
performed a second treatment in one patient in whom a lesion
remained FDG-PET positive after treatment. At the moment,
after our assessment of the value of FDG-PET after local
ablative therapy, we now actually do administer a second
ablative treatment on any lesions that remain positive.
During further follow-up after local tumor ablation, 11 pa-
tients developed recurrent disease in the liver outside the treated
area. All recurrences were detected by FDG-PET as well as by
CT. The time of detection, however, varied between FDG-PET
and CT. The mean time point of detection by FDG-PET was 8.1
months, compared with 11.7 months with CT. In two patients, a
surgical reintervention was performed; in the other nine patients,
chemotherapy was started.
In cases of extrahepatic tumor recurrence, FDG-PET also
seemed to be a sensitive modality. In all nine patients who
developed extrahepatic recurrence, FDG-PET scans were posi-
tive; in one patient, a false-positive outcome was observed
because of an extrahepatic abscess. One extrahepatic recurrence
(pulmonary metastases) was initially missed on the CT scan but
detected by FDG-PET. In retrospect, these pulmonary metasta-
ses could be seen on the CT scan. The mean time point of
detection of extrahepatic recurrence by FDG-PET was 8.4
months, compared with 9.8 months for CT. Two patients with
pulmonary metastases underwent resection during follow-up.
The other patients received chemotherapy.
Thus, in addition to the predictive value of immediate FDG-
PET in the detection of local tumor recurrence in the liver after
tumor ablation, there may also be a role for FDG-PET during
further follow-up. Recurrences of disease outside the local
ablated area are also detected earlier by FDG-PET than by CT.
In our series, four patients underwent surgical reintervention after
the detection of recurrent disease outside the local ablated area.
Since FDG is not a tumor-specific substance, an inflammatory
process also accumulates the tracer due to increased metabolic
activity of leukocytes and macrophages. This is the major
well-known source of false-positive FDG-PET results. We also
observed two false-positive FDG-PET results, once due to
abscess formation in the treated area of the liver and once due to
an extrahepatic abscess in the abdomen. These two false-positive
FDG-PET readings did not result in a treatment alteration,
because FDG-PET was not considered the decisive modality
during this study. Postponing the FDG-PET study in case of
evidence of active focal infection may prevent false-positive
FDG-PET readings. Another limitation of FDG-PET is the
limited spatial resolution, which may lead to false-negative
reports when the lesions are small ( 1 cm). False-negative
results may also occur because of an increased fasting blood
glucose level or manifest diabetes mellitus. In some studies,
patients with diabetes were therefore excluded. Two of the
patients in this study had diabetes mellitus. No false-negative
results were observed in these patients during follow-up. How-
ever, blood glucose levels were always checked as we were
aware of this potential source of error.
For over a decade it has been recognized that PET can be used
to detect recurrences from colorectal cancer after FDG admin-
istration.19 With regard to extrahepatic recurrence, some studies
even demonstrate that FDG-PET is more sensitive than conven-
tional cross-sectional imaging methods.20,21 Delbeke et al22
found in a series of 52 patients with recurrent colorectal cancer
that FDG-PET was more accurate than CT for the detection of
extrahepatic disease (92% v 71%, respectively). Fong et al23
showed unexpected extrahepatic disease detected by FDG-PET
in 10 of 40 patients. This finding was confirmed by others.24,25
We showed in a recent prospective study that FDG-PET led to
clinically relevant extrahepatic findings different from those
found with conventional imaging in nine of 51 patients analyzed
for hepatic resection of colorectal liver metastases. In this
study, FDG-PET findings led to a change in clinical manage-
ment in 20% of patients.26 In the present study, we confirm
our earlier observation and show furthermore that FDG-PET
reveals extrahepatic recurrences earlier than CT.
For the detection of liver metastases, however, the value of
FDG-PET has not been fully determined. Spiral CT is currently
regarded as the best method for evaluating the anatomy and
resectability of colorectal liver metastases. The extent of liver
involvement and the relationship of the metastases to the biliary
and vascular structures generally determine resectability of liver
metastases. Therefore, given the limited anatomic information
provided at this stage by FDG-PET, FDG-PET by itself will not
become a substitute for the anatomic imaging provided by CT.
With regard to sensitivity of tumor detection, however, several
authors have reported a higher accuracy for FDG-PET compared
with spiral CT. In a series by Vitola et al,27 the sensitivity for the
detection of liver metastases by FDG-PET and CT was 93% and
76%, respectively. In a study by Hustinx et al,28 the values were
92% and 85%, respectively. However, sensitivity of FDG-PET
for colorectal liver metastases is considered to be directly related
to tumor size, as described by Fong et al.23 They found that in
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lesions less than 1 cm the sensitivity of FDG-PET decreased
considerably to 21%. Surprisingly, our current study shows an
early detection of liver recurrence, so FDG-PET was able to
detect recurrences even when the lesions were small. An
explanation may be the relatively high contrast of FDG-accu-
mulating tumor remnants as compared with the photopenic
background of the CSA and RFA lesions, which facilitate
identification of pathologic uptake.
In this study, we routinely performed two-phase CT, as is
generally recommended in the follow-up of patients after RFA of
colorectal liver metastases.29 This is in contrast to treatment of
patients with suspected recurrence of hepatocellular carcinoma
after local tumor ablation. For hepatocellular carcinoma, three-
phase CT is recommended because recurrence is best depicted in
the early arterial phase.30 As stated by Chopra et al,31 however,
arterial phase images are not recommended in patients with
colorectal liver metastases after radiofrequency because they do
not provide any additional information.
In our series, local recurrence after local tumor ablation was
observed in 17% of the patients during a follow-up period of at
least 16 months. Lesion-based analysis showed a local recur-
rence rate of 7% after local tumor ablation. This value for local
recurrence is low in comparison with a local recurrence rate of
44% described by Adam et al.15 Others, however, have also
reported local recurrence rates on a lesion basis as low as 2.5%
to 9%.14,32
In conclusion, it seems that FDG-PET performed early after
treatment provides additional information about the efficacy of
local tumor ablation by differentiating posttreatment changes
from residual or recurrent malignant tumor. This study also
provides evidence that FDG-PET has an added value in the
detection of tumor recurrence during follow-up. FDG-PET
reveals hepatic recurrences in or outside the treated area as well
as extrahepatic recurrences earlier than conventional follow-up,
ie, CT and CEA measurement.
The present study suggests that FDG-PET may become the
primary diagnostic tool to detect local recurrence after CSA
or RFA, guiding the determination of whether other imaging
techniques are needed (in case of a positive FDG-PET scan).
However, larger studies are needed to define the precise
impact of FDG-PET as a follow-up measure after local
ablative therapy.
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